Fabio Macaluso avvocato italiano (1963-)
Macaluso, Fabio
VIAF ID: 309577993 (Personal)
Permalink: http://viaf.org/viaf/309577993
Preferred Forms
- 100 0 _ ‡a Fabio Macaluso ‡c avvocato italiano (1963-)
- 200 _ 1 ‡a Macaluso ‡b , Fabio
- 200 _ | ‡a Macaluso ‡b Fabio
- 100 1 _ ‡a Macaluso, Fabio
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. | |
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease | |
Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. | |
The biologics of ulcerative colitis | |
Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. | |
Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort | |
Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study | |
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. | |
Dizionario della privacy : 53 brevi saggi sulla protezione dei dati personali / Fabio Macaluso, Jacopo Purificati ; prefazione di Raffaele Barberio | |
E Mozart finì in una fossa comune vizi e virtù del copyright | |
Education and Imaging. Hepatobiliary and pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. | |
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study | |
Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. | |
Hangar : e.p. / Fabio Macaluso | |
The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. | |
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. | |
Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report | |
Herbal hepatotoxicity: a hidden epidemic. | |
How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey | |
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection | |
Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis? | |
Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. | |
Letter: mesalazine-a safe drug with rare serious adverse events | |
Letter: propensity score-handle with care | |
Letter: psoriasiform eruption during vedolizumab therapy | |
Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2 | |
Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure. | |
Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature | |
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. | |
Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease | |
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. | |
Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems | |
Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. | |
A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn's disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) | |
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases | |
Il Regolamento dell’Autorità delle Garanzie nelle comunicazioni in materia di diritto d’autore e la libertà di espressione | |
Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. | |
Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review | |
Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities | |
Screening of colorectal cancer: present and future. | |
The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long? | |
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease | |
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients | |
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. | |
Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience | |
The VERSIFY Trial: What About Ultrasound Assessment? |